The Study of Folate Receptor-Mediated Staining Solution (FRD™) In Cervical Lesion Detection
NCT03366493 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 200
Last updated 2017-12-08
Summary
The FRDTM is easy to perform and does not require sophisticated laboratory technology and/or experienced pathologists for test result interpretation. Compared to the Pap smear and HPV test, the FRDTM enables clinicians to obtain test results immediately (within 60 seconds) after the screening. This empowers clinicians in making timely decisions on appropriate patient management, and facilitating patient compliance with follow-up procedures. In addition, the FRDTM requires minimal training and technical support. Due to its advantage of rapid visualization of abnormal cervical lesions (CIN2+) in a cost-effective way, health care professionals can make cervical cancer detection accessible to women worldwide, especially in regions with limited medical resources. This is a cross-sectional study to evaluate the clinical performance of Folate Receptor-Mediated Epithelium Staining (FRDTM) in detecting cervical neoplastic lesions (CIN2+).
Conditions
- Cervical Intraepithelial Neoplasia Grade 2/3
Interventions
- COMBINATION_PRODUCT
-
FRD
The Folate Receptor-Mediated Staining Solution is a dye solution that stains for medical purposes used in staining cells and tissues for detecting neoplastic diseases. After inserting a speculum into your vagina, the FRD™ staining solution will be applied to the cervix using an applicator. After removal of the applicator, the doctor will inspect the applicator for color changes and note any changes. The physician will then remove any excess stain from the cervix using distilled water.
- OTHER
-
Cytology
Cytology testing done by collecting samples of cells, and smearing those samples across a glass microscope slide in order to detect abnormal cells that may develop into cervical cancer.
- OTHER
-
HPV testing
HPV tests will detect HPV infections, which can lead to cervical cells to become cancer cells.
- PROCEDURE
-
Colposcopy
During the colposcopic examination, the physician will insert a speculum into the vagina and then apply a vinegar solution to the cervix. The vinegar solution causes any potential abnormal cells to turn white. These white regions are best seen using the colposcope, which magnifiesthe skin.
- PROCEDURE
-
ECC
If the examination is not satisfactory and the doctor is not able to see the entire cervix, he may perform an endocervical curettage, or ECC. This sample is collected by placing a long, thin instrument into the cervical canal and a sample is scraped from that area. The sample will be sent to the laboratory for a pathologist to review.
- PROCEDURE
-
Biospy
According to the colposcopy assessment, if the doctor sees a white area, or an area of abnormal cells, a tiny sample of tissue, called a biopsy will be taken from the cervix. About half of women do not feel the biopsy being taken. Others may feel a quick pinch. After the biopsy, the wound will be treated to stop bleeding.The biopsy will be sent to the laboratory for a pathologist to review.
Sponsors & Collaborators
-
GY Highland Biotech LLC
lead INDUSTRY
Principal Investigators
-
Daron G Ferris, MD · Augusta University
Study Design
- Allocation
- RANDOMIZED
- Purpose
- SCREENING
- Masking
- NONE
- Model
- CROSSOVER
Eligibility
- Min Age
- 20 Years
- Max Age
- 60 Years
- Sex
- FEMALE
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2017-12-07
- Primary Completion
- 2018-12-07
- Completion
- 2018-12-07
Countries
- United States
Study Locations
More Related Trials
-
Combined Digital Colposcopy Analysis to Improve Cervical Precancer and Cancer Detection
NCT01094132 ·Status: COMPLETED ·Phase: PHASE2
-
Non-Invasive Plasma Treatment for Cervical Infections: Targeting High- and Low-Risk HPV Variants
NCT06291311 ·Status: RECRUITING
-
A Multicenter Real-world Study of Screening of Cervical Cancer Based on Photoelectric Detection
NCT06481930 ·Status: NOT_YET_RECRUITING
-
Cervical Cancer Prevention: From DNA to mRNA? - New Technologies for Cervical Cancer Screening 2
NCT01837693 ·Status: COMPLETED ·Phase: NA
-
HRME: Screening for Cervical Cancer and Its Precursors in Low-Resource Settings
NCT02494310 ·Status: COMPLETED ·Phase: NA
-
Imiquimod Treatment of CIN Lesions
NCT02329171 ·Status: TERMINATED ·Phase: PHASE3
-
Screening Test Accuracy of Gynocular™, HR-HPV Testing, VIA for Detection of Cervical Neoplastic Lesions, in Women Living With HIV
NCT03931083 ·Status: UNKNOWN
-
Non-Invasive, Real-Time Technology for Diagnosis of Cervical Tissue
NCT00250055 ·Status: TERMINATED ·Phase: NA
-
FDG-PET and Circulating HPV in Patients With Cervical Cancer
NCT02388698 ·Status: UNKNOWN ·Phase: NA
-
Evaluation of Initial High Risk Human Papillomavirus (HR-HPV) Viral Load as Predictive Marker for Cervical Intraepithelial Neoplasia Grade 1 (CIN1) Persistence
NCT00682552 ·Status: TERMINATED ·Phase: NA
-
Positron Lymphography Via Intracervical 18F-FDG Injection for Pre-surgical Lymphatic Mapping in Stage IB1 Cervical Cancer and High-grade Endometrial Cancer
NCT02285192 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Expectancy as Alternative to Treatment for Cervical Intraepithelial Neoplasia Grade 2 Among Women 25 - 30 Years of Age
NCT03177863 ·Status: COMPLETED ·Phase: NA
-
ctDNA Liquid Biopsy for Early Assessment of Residual Disease in HPV-associated Head and Neck Cancer (Clear-HPVca)
NCT06730412 ·Status: COMPLETED
-
Feasibility of Delphi Screener for Cervical Cytology
NCT00702208 ·Status: COMPLETED ·Phase: PHASE2
-
TMTP1-ICG Mapping in Colposcopy-directed Biopsy
NCT03321461 ·Status: UNKNOWN ·Phase: PHASE1
-
HRME in the Screening of Cervical Cancer Precursor Lesions in Brazil (UH3 - Brazil)
NCT03195218 ·Status: UNKNOWN ·Phase: NA
-
Low-cost Imaging Technology for Global Prevention of Cervical Cancer
NCT05078528 ·Status: RECRUITING ·Phase: NA
-
HPV Serum Level and FDG PET CT in Patients With Cervical Cancer Treated With Radical Radiochemotherapy
NCT04683549 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Human Papilloma Virus (HPV) Circulating Tumor DNA (ctDNA) in Cervical Cancer
NCT04574635 ·Status: ACTIVE_NOT_RECRUITING
-
Using Plasma Human Papillomavirus (HPV)-Related Deoxyribonucleic Acid (DNA) and Ribonucleic Acid (RNA) to Follow Response of Cervical Cancer to Surgery, Radiation, and Chemotherapy
NCT07214584 ·Status: RECRUITING
-
Advancing Cervical Cancer Screening Through the Emergency Department - IIS
NCT06796738 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Randomized Implementation of Primary HPV Testing in the Organized Screening for Cervical Cancer in Stockholm
NCT01511328 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Significance of Fluorescence Colposcopy With Autofluorescence Imaging for Cervical Cancer
NCT01854983 ·Status: COMPLETED
-
Preventing Invasive Cervical Cancer: The Importance of Expectant Management in Young Women With High-grade Pre-cancerous Lesions
NCT03920800 ·Status: COMPLETED
-
Fluorescence and Reflectance Spectroscopy During Colposcopy in Detecting Cervical Intraepithelial Neoplasia and Dysplasia in Healthy Participants With a History of Normal Pap Smears
NCT00084903 ·Status: COMPLETED ·Phase: NA